{"prompt": "['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'options will be on a 7 point Likert scale ranging from much better to much worse. Asking', 'at each Visit allows for early detection of response as well as continued response.', '9.2.', 'Adverse Events', 'The definitions of an AE or SAE can be found in Appendix 4 (Section 12.4).', 'The investigator and any designees are responsible for detecting, documenting, and', 'reporting events that meet the definition of an AE or SAE and remain responsible for', 'following up AEs that are serious, considered related to the study treatment or the study,', 'or that caused the participant to discontinue the study treatment (see Section 8).', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', 'All SAEs will be collected from the time the informed consent is signed by the', 'participant until the follow up visit at the time points specified in the SoA', '(Table 1).', 'All AEs will be collected from the start of study treatment (randomization visit)', 'until the follow-up visit at the time points specified in the SoA (Table 1).', 'Medical occurrences that begin before the start of study treatment but after', 'obtaining informed consent will be recorded on the Medical History/Current', 'Medical Conditions section of the case report form (CRF) not the AE section.', 'All SAEs must be reported immediately and not more than 24 hrs to the sponsor,', 'as indicated in Appendix 4 (Section 12.4). The investigator will submit any', 'updated SAE data to the sponsor within 24 hours of it being available.', 'Investigators are not obligated to actively seek AEs or SAEs in former study', 'participants. However, if the investigator learns of any SAE, including a death,', 'at any time after a participant has been discharged from the study, and he/she', 'considers the event to be reasonably related to the study treatment or study', 'participation, the investigator must promptly notify the sponsor.', 'The method of recording, evaluating, and assessing causality of AEs and SAEs', 'and the procedures for completing and transmitting SAE reports are provided in', 'Appendix 4 (Section 12.4).', '9.2.2.', 'Method of Detecting AEs and SAEs', 'Care will be taken not to introduce bias when detecting AE and/or SAE. Open-ended and', 'non-leading verbal questioning of the participant is the preferred method to inquire about', 'AE occurrence.', '9.2.3.', 'Follow-up of AEs and SAEs', 'After the initial AE/SAE report, the investigator is required to proactively follow each', 'participant at subsequent visits/contacts. All SAEs will be followed until the event is', '38']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'resolved, stabilized, otherwise explained, or the participant is lost to follow-up (as', 'defined in Section 8.3). Further information on follow-up procedures is given in', 'Appendix 4.', '9.2.4.', 'Regulatory Reporting Requirements for SAEs', 'Prompt notification by the investigator to the sponsor of a SAE is essential so', 'that legal obligations and ethical responsibilities towards the safety of', 'participants and the safety of a study treatment under clinical investigation are', 'met.', 'The sponsor has a legal responsibility to notify both the local regulatory', 'authority and other regulatory agencies about the safety of a study treatment', 'under clinical investigation. The sponsor will comply with country-specific', 'regulatory requirements relating to safety reporting to the regulatory authority,', 'Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and', 'investigators.', 'Investigator safety reports must be prepared for suspected unexpected serious', 'adverse reactions (SUSAR) according to local regulatory requirements and', 'sponsor policy and forwarded to investigators as necessary.', 'An investigator who receives an investigator safety report describing a SAE or', 'other specific safety information e.g., summary or listing of SAE) from the', \"sponsor will review and then file it along with the Investigator's Brochure and\", 'will notify the IRB/IEC, if appropriate according to local requirements.', '9.2.5.', 'Cardiovascular and Death Events', 'For any cardiovascular events detailed in Section 12.4 (Appendix 4) and all deaths,', 'whether or not they are considered SAEs, specific Cardiovascular (CV) and Death', 'sections of the CRF will be required to be completed. These sections include questions', 'regarding cardiovascular (including sudden cardiac death) and non-cardiovascular death.', 'The CV CRFs are presented as queries in response to reporting of certain CV MedDRA', 'terms. The CV information should be recorded in the specific cardiovascular section of', 'the CRF within one week of receipt of a CV Event data query prompting its completion.', '9.2.6.', 'Disease-Related Events and/or Disease-Related Outcomes Not', 'Qualifying as SAEs', 'The following disease related events (DREs) are common in participants with COPD and', 'can be serious/life threatening:', 'COPD exacerbations', 'Because these events are typically associated with the disease under study, they will not', 'be reported according to the standard process for expedited reporting of SAEs to GSK', '(even though the event may meet the definition of an SAE). These events will be', \"recorded on the DRE page in the participant's CRF within 72 hours after the investigator\", '39']\n\n###\n\n", "completion": "END"}